119
Participants
Start Date
March 11, 2009
Primary Completion Date
April 27, 2012
Study Completion Date
April 30, 2015
Dacomitinib (PF-00299804)
Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
Dacomitinib (PF-00299804)
In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
Department of Clinical Oncology, Tuen Mun Hospital, Tuenmen
National Taiwan University Hospital, Taipei
Memorial Sloan-Kettering Cancer Center, New York
National Institutes of Health National Cancer Institute, Bethesda
Virginia Cancer Institute, Richmond
Investigational Drug Service, Pharmacy Department, UNC Hospitals, Chapel Hill
Morris Cancer Center, Durham
Florida Cancer Specialists, Fort Myers
Chattanooga Oncology & Hematology Associates, P.C., Chattanooga
Legacy Pharma Research, Bismarck
Mid Dakota Clinic, P.C, Bismarck
St. John's Hospital,, Springfield
University of Colorado Clinical Trials Office (CTO), Aurora
University of Colorado Hospital, Aurora
Chao Family Comprehensive Cancer Center UC Irvine Medical Center, Orange
Pacific Cancer Care, Salinas
San Francisco General Hospital, San Francisco
Bay Area Cancer Research Group, LLC, Pleasant Hill
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
University of California, Irvine, Orange
Massachusetts General Hospital, Boston
Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer lnstitute, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Stony Brook University Medical Center - Cancer Center, Stony Brook
Division of Hemotology/Oncology, Chapel Hill
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
Sarah Cannon Research Institute, Nashville
Sarah Cannon Research Institute, Nashville
Department of Clinical Oncology, Tuen Mun Hospital, Tuenmen
Department of Clinical Oncology, Tuen Mun Hospital, New Territories
Prince of Wales Hospital, Shatin, NT
The Cancer Institute Hospital of JFCR, Koto-Ku
Aichi cancer center central hospital Thoracic Oncology, Aichi
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul
SamsungMedicalCenter, Sungkyunkwan Univ School of Medicine, Seoul
Lead Sponsor
Pfizer
INDUSTRY